ENTERA BIO LTD. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
ENTERA BIO LTD. (ENTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $147.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-08-11.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2022-08-11
- ENTERA BIO LTD. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-03-31 was $147.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month as first filed |
|---|---|---|
| 2022-03-31 | $147.00K 10-Q · filed 2022-08-11 | $274.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |